Caroline Palomeque
Stock Analyst at Maxim Group
(1.22)
# 3,666
Out of 5,174 analysts
10
Total ratings
44.44%
Success rate
-4.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $1.36 | +488.24% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $27.10 | +117.71% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $247.09 | -37.67% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $62.04 | -6.51% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $215.54 | -22.98% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $20.97 | +85.98% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $7.81 | +681.05% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $4.19 | +854.65% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $1.36
Upside: +488.24%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $27.10
Upside: +117.71%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $247.09
Upside: -37.67%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $62.04
Upside: -6.51%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $215.54
Upside: -22.98%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $20.97
Upside: +85.98%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $7.81
Upside: +681.05%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $4.19
Upside: +854.65%